Skip to main
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics is a promising company due to their advanced drug pipeline focused on targeting specific genetic abnormalities through their proprietary platform. The success of FHD-909 in clinical trials and partnership with Eli Lilly bodes well for their potential success in the market. However, there is still uncertainty about the efficacy and commercialization of their drugs, and the company will need to continue to develop and prove the effectiveness of their targeted therapies.

Bears say

Foghorn Therapeutics is a relatively new company in the biotechnology industry and is still in its early stages as a clinical-stage precision therapeutics company. However, the recent discontinuation of its flagship program FHD-286 in early phase clinical trials for two different types of cancer and the lack of any current drug candidates in its pipeline raise concerns about the company's potential for success in the future. Additionally, the dependence on regulatory approvals for its treatments and the high development costs associated with this industry further add to the risk of investing in Foghorn Therapeutics's stock.

Foghorn Therapeutics (FHTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.